Citigroup’s IO Biotech IOBT Stock Holding History

Citigroup’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-72,495	Closed	-$4.25K	–	5989
2026 Q1	$4.25K	Sell	72,495 -38,952	-35%	-$13.3K	﹤0.01%	5296
2025 Q4	$67.9K	Buy	111,447 +110,155	+8,526%	+$81.9K	﹤0.01%	4477
2025 Q3	$469	Buy	1,292 +978	+311%	+$1.69K	﹤0.01%	5714
2025 Q2	$436	Buy	+314	New	+$360	﹤0.01%	5448
2025 Q1	–	Sell	-5	Closed	-$5	–	5765
2024 Q4	$5	Buy	+5	New	+$5	﹤0.01%	5785
2022 Q3	–	Sell	-1,000	Closed	-$5K	–	6070
2022 Q2	$5K	Buy	1,000 +836	+510%	+$5.12K	﹤0.01%	5615
2022 Q1	$1K	Buy	+164	New	+$1.08K	﹤0.01%	6179

Citigroup's IOBT Position: Q2 2026 in Review

Citigroup sold out of IO Biotech (IOBT) in Q2 2026, closing a stake of 72,495 shares — an estimated $4.25K sold.

Citigroup first reported a position in IOBT in Q1 2022 and held it in 7 quarters. The position peaked at $67.9K in Q4 2025. 0 funds tracked by Wall St. Rank hold IOBT as of Q2 2026.

Citigroup reported no remaining IO Biotech position as of Q2 2026 after selling out during the quarter.
Citigroup sold 72,495 IO Biotech shares in Q2 2026, an estimated $4.25K.
Citigroup first reported a position in IO Biotech in Q1 2022 and held it in 7 quarters.
Citigroup's IO Biotech position peaked at $67.9K in Q4 2025.
0 funds tracked by Wall St. Rank held IO Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.